Clinical Trials on Methicillin Susceptible Staphylococcus Aureus Septicemia in Chile

Total 4 results

Pfizer

Completed

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Skin/Soft Tissue Infections | Methicillin Resistant Staphylococcus Aureus (MRSA)

United States, Spain, United Kingdom, Colombia, Italy, Chile, Argentina, Mexico, Belgium, Russian Federation, Brazil, Malaysia, Singapore, Portugal, South Africa, Venezuela
Pfizer

Completed

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA) (ZEPHYR)

Methicillin Resistant Staphylococcus Aureus (MRSA)

United States, Greece, Colombia, Korea, Republic of, Russian Federation, Turkey, Brazil, Chile, Taiwan, Mexico, Belgium, Spain, Hong Kong, Puerto Rico, France, United Kingdom, Malaysia, Germany, South Africa, Portugal, Argentina, ...
ContraFect

Completed

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Staphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis

United States, Belgium, Bulgaria, Chile, Czechia, France, Germany, Greece, Guatemala, Israel, Italy, Russian Federation, Spain, United Kingdom
AbbVie

Completed

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Bacterial Infections | Staphylococcal Skin Infections | Methicillin-Resistant Staphylococcus Aureus

United States, Bulgaria, Chile, Colombia, Georgia, Greece, Guatemala, Latvia, Mexico, Panama, Spain, Ukraine

Clinical Trials on Methicillin Susceptible Staphylococcus Aureus Septicemia in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations